Diabetes Remission Increased With Dapagliflozin Plus Calorie Restriction
MONDAY, Jan. 27, 2025 -- For patients with overweight or obesity and type 2 diabetes, dapagliflozin plus regular calorie restriction is associated with a significantly higher rate of remission of diabetes compared with calorie restriction alone, according to a study published online Jan. 22 in The BMJ.
Yuejun Liu, from Fudan University in Shanghai, and colleagues conducted a multicenter, double-blind randomized trial in 16 centers in China from June 12, 2020, to Jan. 31, 2023, involving 328 patients with type 2 diabetes aged 20 to 70 years, with body mass index >25 kg/m2 and diabetes duration of less than six years. Patients were randomly assigned to calorie restriction with dapagliflozin 10 mg/day or placebo.
The researchers found that diabetes remission was achieved in 44 and 28 percent of patients in the dapagliflozin and placebo groups, respectively, over 12 months (risk ratio, 1.56), meeting the predefined primary end point. Significantly greater changes in body weight (difference, −1.3 kg) and homoeostasis model assessment of insulin resistance (difference, −0.8) were seen in the dapagliflozin versus placebo group. Likewise, compared with the placebo group, significantly more improvement was seen in body fat, systolic blood pressure, and metabolic risk factors in the dapagliflozin group. The occurrence of adverse events did not differ between the groups.
"Our findings provide an alternative and more practical strategy than intensive weight management to achieve remission for patients with early type 2 diabetes," the authors write.
The study was partially funded by AstraZeneca, the manufacturer of dapagliflozin.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Once-Weekly Semaglutide 7.2 mg Beats Placebo for Obesity
THURSDAY, Sept. 18, 2025 -- In adults with obesity and those with type 2 diabetes and obesity, once-weekly semaglutide 7.2 mg is superior to placebo for body weight reduction...
GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity
WEDNESDAY, Sept. 17, 2025 -- Compared with usual care, the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) tirzepatide and semaglutide are cost-effective for people with...
Without Biannual Time Shift, Prevalence of Obesity, Stroke May Be Reduced
WEDNESDAY, Sept. 17, 2025 -- The prevalence of obesity and stroke would be reduced with permanent Standard Time (SDT) and Daylight Saving Time (DST) compared with the current...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.